Joint venture · GCC · Announced 3 May 2026
LifePharma → Burjeel
Joint venture deal between LifePharma (United Arab Emirates) and Burjeel (United Arab Emirates), covering EQUIGENE Therapeutics, announced 3 May 2026. Value: $27.2m.
Parties: LIFEPHARMA FZE (United Arab Emirates) → Burjeel Holdings (United Arab Emirates)
- Deal type
- Joint venture
- Value
- $27.2m
- Territory
- United Arab Emirates (Abu Dhabi); development leverages the UAE–India healthcare corridor (UAE regulatory ecosystem + India's patient base and cost base)
- Therapeutic area
- Rare / Orphan
- Asset
- EQUIGENE Therapeutics — a gene-therapy platform/pipeline for rare inherited blood disorders. No single named molecule yet; a scalable vector-and-cell processing model spanning clinical trials to commercial product.
- Announced
- 3 May 2026
Our analysis
Why this matters.
At Make it in the Emirates 2026, UAE manufacturer LIFEPharma and Burjeel Holdings launched EQUIGENE Therapeutics — billed as the region's first gene-therapy initiative — aimed squarely at rare inherited blood disorders like sickle cell disease and beta-thalassemia.
The full analysis is free to read with a work email on this page.
Source: Zawya